Jeffrey Tong
InvestorPartner at Third Rock Ventures · Board director at Septerna · Executive at Nora Therapeutics
West Coast
Writes $100K – $5M checks · typically $1.5M
Find your path to Jeffrey
770 people in our graph share verified history with Jeffrey — schools, employers, funds. One of them is your warm intro.
About
Jeffrey Tong is a Partner at Third Rock Ventures, where he draws on operational experience building and growing early-stage biotechnology companies to focus on drug discovery and development across the firm's portfolio. Before joining Third Rock in 2016, he was Executive Chairman of Delinia, CEO of Nora Therapeutics, and part of the founding management team at Infinity Pharmaceuticals. Earlier in his career he worked at McKinsey & Co and was a founding researcher at the Harvard Bauer Center for Genomics Research. Across his career he has raised capital from equity markets and pharma partnerships and led companies from preclinical through Phase 3 development, integrating science and business strategy.
Contact· published on Jeffrey's own website
Beyond investing
- Education
- Earned an A.B. from Harvard College. Earned an A.M. from Harvard University. Earned an M.M.S. from Harvard Medical School. Earned a Ph.D. from Harvard University.
From Jeffrey's own website — common ground for a warm intro.
Board director at Septerna
Intro paths
In turn, Jeffrey can intro founders to Septerna's investors below.
Septerna's investors · 5
Co-founders at Septerna
Executive at Nora Therapeutics
Experience
- Third Rock VenturesPartnercurrent2016 — presentSan Francisco Bay Area
- DeliniaExecutive Chairman of the Board2016 — 2017San Francisco and Boston
- Nora TherapeuticsMember of the Board of Directors2010 — 2016San Francisco Bay Area
- Nora TherapeuticsPresident & CEO2010 — 2015San Francisco Bay Area
- Infinity PharmaceuticalsVice President, Corporate and Product Development2001 — 2010Greater Boston Area
- McKinsey & CompanyConsultant2000 — 2001San Francisco Bay Area
Deals · 1
SepternaBoard seat
via Third Rock Ventures · filed Jul 2023 · $150M raise
Attribution from SEC filings, press coverage, and firm rosters.
Other disclosed investments
Investor
Ambys MedicinesARTBIOAsher BioMarea TherapeuticsTakkoTerremotobioTrace Neuroscience
Sources: SEC Form D filings · curated public sources.
Colleagues at Third Rock Ventures
Frequently asked questions
- Who is Jeffrey Tong?
- Jeffrey Tong is a Partner at Third Rock Ventures, where he draws on operational experience building and growing early-stage biotechnology companies to focus on drug discovery and development across the firm's portfolio. Before joining Third Rock in 2016, he was Executive Chairman of Delinia, CEO of Nora Therapeutics, and part of the founding management team at Infinity Pharmaceuticals. Earlier in his career he worked at McKinsey & Co and was a founding researcher at the Harvard Bauer Center for Genomics Research. Across his career he has raised capital from equity markets and pharma partnerships and led companies from preclinical through Phase 3 development, integrating science and business strategy.
- Where does Jeffrey Tong work?
- Jeffrey Tong is Partner at Third Rock Ventures and Board director at Septerna and Executive at Nora Therapeutics.
- What check size does Jeffrey Tong write?
- Jeffrey Tong typically writes checks of $100K – $5M.
- What boards does Jeffrey Tong sit on?
- Jeffrey Tong holds tracked board seats at Septerna.
- What companies has Jeffrey Tong invested in?
- Investments tracked here include Ambys Medicines, ARTBIO, Asher Bio, Marea Therapeutics, Septerna, Takko, Terremotobio, Trace Neuroscience.
- Where did Jeffrey Tong go to school?
- Jeffrey Tong studied at Harvard University (AB, AM, MMS, PhD).
Founder mafias
McKinsey & Company mafia736
Also came through, then founded or led a company.
+ 729 more
Third Rock Ventures mafia23
Also came through, then founded or led a company.
+ 16 more
Same school
Also attended Harvard University2,000
+ 1,994 more
Shared employers
Also worked at Infinity Pharmaceuticals11
+ 5 more
Also worked at McKinsey & Company2,000
+ 1,994 more